1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 25,600 | 28,600 | 06.02. | |
| 26,400 | 29,600 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.01. | Burning Rock Biotech Limited: Burning Rock Announces Founder's Purchase of Its ADSs | 164 | GlobeNewswire (Europe) | GUANGZHOU, China, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing... ► Artikel lesen | |
| 23.12.25 | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.12.25 | Burning Rock Biotech Limited: Burning Rock Announces Results of 2025 Annual General Meeting | 105 | GlobeNewswire (Europe) | GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing... ► Artikel lesen | |
| BURNING ROCK BIOTECH Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.12.25 | Burning Rock Biotech Limited: Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025 | 1 | GlobeNewswire (USA) | ||
| 28.11.25 | Burning Rock Stock Up 35%+ As Loss Narrows | 1 | Benzinga.com | ||
| 28.11.25 | Neglected Burning Rock charms investors with high margins, narrowing losses | 1 | Bamboo Works | ||
| 20.11.25 | Burning Rock Biotech GAAP EPS of -$0.02, revenue of $18.49M | 1 | Seeking Alpha | ||
| 20.11.25 | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.11.25 | Burning Rock Biotech Limited: Burning Rock Reports Third Quarter 2025 Financial Results | 162 | GlobeNewswire (Europe) | GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen | |
| 24.09.25 | Burning Rock Biotech Limited: Burning Rock's OncoGuide OncoScreen Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer | 2 | GlobeNewswire (USA) | ||
| 08.09.25 | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.09.25 | Burning Rock Biotech Loss Shrinks In Q2 | - | RTTNews | ||
| 08.09.25 | Burning Rock Biotech Limited: Burning Rock Reports Second Quarter 2025 Financial Results | 384 | GlobeNewswire (Europe) | GUANGZHOU, China, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen | |
| 06.06.25 | Burning Rock Biotech Q1 Loss Narrows, Revenue Improves | 488 | AFX News | BEIJING (dpa-AFX) - Burning Rock Biotech Limited (BNR) Friday reported loss before tax of RMB 13.28 million for the first quarter, significantly lower than RMB 121.37 million loss in the same... ► Artikel lesen | |
| 06.06.25 | Burning Rock Biotech Limited: Burning Rock Reports First Quarter 2025 Financial Results | 1.185 | GlobeNewswire (Europe) | GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen | |
| 25.03.25 | Burning Rock Biotech Limited Q4 Loss Drops | 471 | AFX News | BEIJING (dpa-AFX) - Burning Rock Biotech Limited (BNR) released Loss for fourth quarter of -RMB81.29 millionThe company's bottom line came in at -RMB81.29 million, or -RMB0.79 per share. This... ► Artikel lesen | |
| 25.03.25 | Burning Rock Biotech Limited: Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results | 373 | GlobeNewswire (Europe) | GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| MEDIGENE | 0,042 | -8,26 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 43,170 | -0,70 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 662,80 | -0,27 % | REGENERON PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,320 | -0,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| GENMAB | 263,50 | +0,84 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025 | Company Announcement Net sales of DARZALEX- in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN... ► Artikel lesen | |
| EDITAS MEDICINE | 1,536 | +0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,392 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | ||
| DYNAVAX | 13,085 | -0,19 % | Laufende Fusionskontrollverfahren: Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USA | Datum der Anmeldung:05.01.2026Aktenzeichen:B3-21/26Unternehmen:Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USAProduktmärkte:monovalenter... ► Artikel lesen |
Das Unternehmen BURNING ROCK BIOTECH LTD ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +1,600 (+5,71 %) liegt der Kurs bei 29,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BURNING ROCK BIOTECH LTD ADR finden Sie auf Wallstreet Online.